Pages that link to "Hit to lead"
Showing 50 items.
- NMDA receptor (links | edit)
- Drug discovery (links | edit)
- Drug design (links | edit)
- Preclinical development (links | edit)
- Natural product (links | edit)
- Lead generation (links | edit)
- Drug development (links | edit)
- Enzyme inhibitor (links | edit)
- Hit to lead (transclusion) (links | edit)
- Lead optimization (redirect to section "Lead optimization phase") (links | edit)
- Pesticide (links | edit)
- Medicinal chemistry (links | edit)
- Hit to lead (links | edit)
- Scoring functions for docking (links | edit)
- Lead compound (links | edit)
- Chemoproteomics (links | edit)
- Jonathan Baell (links | edit)
- Talk:Drug development (links | edit)
- User:Sgold626/Chemoproteomics (links | edit)
- Wikipedia:Articles for deletion/Log/2009 June 10 (links | edit)
- Wikipedia:Articles for deletion/Chemical postevolution (2nd nomination) (links | edit)
- Drug Discovery Hit to Lead (redirect page) (links | edit)
- Pharmacology (links | edit)
- Chemical library (links | edit)
- Talk:Drug design (links | edit)
- Discovery and development of statins (links | edit)
- Discovery and development of ACE inhibitors (links | edit)
- ChemMedChem (links | edit)
- Discovery and development of cyclooxygenase 2 inhibitors (links | edit)
- Discovery and development of angiotensin receptor blockers (links | edit)
- Discovery and development of triptans (links | edit)
- Discovery and development of dipeptidyl peptidase-4 inhibitors (links | edit)
- Carpanone (links | edit)
- CCR5 receptor antagonist (links | edit)
- Discovery and development of non-nucleoside reverse-transcriptase inhibitors (links | edit)
- Discovery and development of HIV-protease inhibitors (links | edit)
- Discovery and development of TRPV1 antagonists (links | edit)
- Derek Lowe (chemist) (links | edit)
- Discovery and development of nucleoside and nucleotide reverse-transcriptase inhibitors (links | edit)
- Melatonin receptor agonist (links | edit)
- Discovery and development of proton pump inhibitors (links | edit)
- Ligand efficiency (links | edit)
- Discovery and development of antiandrogens (links | edit)
- Discovery and development of cephalosporins (links | edit)
- Discovery and development of integrase inhibitors (links | edit)
- C-Met inhibitor (links | edit)
- Phases of clinical research (links | edit)
- 5-HT2C receptor agonist (links | edit)
- Discovery and development of direct thrombin inhibitors (links | edit)
- MTOR inhibitors (links | edit)
- Ross D. King (links | edit)
- Drug discovery hit to lead (redirect page) (links | edit)
- Drug discovery (links | edit)
- Drug design (links | edit)
- Lipinski's rule of five (links | edit)
- High-throughput screening (links | edit)
- Chemogenomics (links | edit)
- MDL Information Systems (links | edit)
- High-content screening (links | edit)
- Compound management (links | edit)
- Lead compound (links | edit)
- High throughput biology (links | edit)
- Ligand efficiency (links | edit)
- Talk:Drug design (links | edit)
- User:Fvasconcellos/Fvasconcellos (links | edit)
- User:Benjah-bmm27/degree (links | edit)
- User:Mogsan1/sandbox (links | edit)
- Wikipedia:WikiProject Pharmacology/Cleanup listing (links | edit)
- H2L (redirect page) (links | edit)
- Discovery and development of phosphodiesterase 5 inhibitors (links | edit)
- Discovery and development of beta-blockers (links | edit)
- GABAA receptor positive allosteric modulator (links | edit)
- Cereblon E3 ligase modulator (links | edit)
- Development and discovery of SSRI drugs (links | edit)
- Discovery and development of gliflozins (links | edit)
- Discovery and development of neuraminidase inhibitors (links | edit)
- Discovery and development of beta2 agonists (links | edit)
- Discovery and development of gastrointestinal lipase inhibitors (links | edit)
- Discovery and development of direct Xa inhibitors (links | edit)
- Discovery and development of NS5A inhibitors (links | edit)